Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supplement seizures

This article was originally published in The Tan Sheet

Executive Summary

FDA seizes 376 cases of Opti-Cran and other herbals valued at $500,999 from Hillestad Pharmaceuticals, the agency announces July 18. FDA had classified the items as "unapproved new drugs represented as dietary" supplements that "fail to bear adequate directions for use." The Woodruff, Wisc.-based firm received a warning letter in 1997 charging its products, including Opti-Cran, were not GRAS/E for their intended uses. FDA also seizes 927 bottles of Metabolite dietary supplement, valued at $32,400, from One World Fulfillment Distribution in Mobridge, S.D. (1see FDA Recalls & Court Actions, p. 18)

You may also be interested in...



Botanicals History Of Use Should Satisfy Food GRAS Requirements - Hutt

More stringent FDA regulation against functional foods containing botanical ingredients is unlikely, attorney Peter Barton Hutt (Covington & Burling) told industry reps Sept. 12.

Botanicals History Of Use Should Satisfy Food GRAS Requirements - Hutt

More stringent FDA regulation against functional foods containing botanical ingredients is unlikely, attorney Peter Barton Hutt (Covington & Burling) told industry reps Sept. 12.

Botanicals History Of Use Should Satisfy Food GRAS Requirements - Hutt

More stringent FDA regulation against functional foods containing botanical ingredients is unlikely, attorney Peter Barton Hutt (Covington & Burling) told industry reps Sept. 12.

Topics

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel